Targeted Leachables Methods: Selection of Analytes and Surrogates

Published on 09/12/2025

Targeted Leachables Methods: Selection of Analytes and Surrogates

Introduction to Extractables and Leachables (E&L)

In the pharmaceutical and biotechnology industries, ensuring the safety and efficacy of products is paramount. One critical area that has gained increasing attention is the extractables and leachables (E&L) testing of materials in contact with drug products. E&L studies are designed to assess the potential risks posed by chemical substances that can leach into pharmaceutical products from packaging, delivery systems, and other components. This comprehensive tutorial focuses on the selection of analytes and surrogates in targeted leachables methods, emphasizing compliance with regulatory expectations such as those set forth by the FDA, EMA, and MHRA.

Understanding Key Concepts: Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT)

The successful execution of E&L studies necessitates a strong grasp of two important thresholds: the analytical evaluation threshold (AET) and the dose-based threshold (DBT). The AET is employed to differentiate between significant and insignificant leachables; it provides a benchmark for identifying which leachables warrant further quantitative analysis. Conversely, the DBT establishes a safety margin for substances, articulating the maximum exposure level acceptable without compromising product safety.

For a robust E&L risk assessment, both thresholds should be defined and justified in relation to the specific application of the drug product and its intended use. Establishing these thresholds is particularly relevant where the safety profile of leachables is in question. It establishes a defensible route for regulatory submissions while aligning with best practices outlined in regulatory documents such as the USP Container Closure Integrity (CCI) guidelines and EU GMP Annex 1.

Step 1: Define the Scope of E&L Testing

The initial step in designing an E&L study is to define the scope clearly, which includes understanding the following:

  • Type of Product: Is the product a biologic, a small molecule drug, or a combination product?
  • Packaging Material: What types of materials (e.g., elastomers, polymers) are utilized in container closure systems or delivery devices?
  • Intended Use: How will the product be used, and what are the potential routes of exposure?

By addressing these elements, stakeholders can streamline their E&L risk assessment to focus on the most pertinent analytes and surrogates. In line with the PQRI guideline and complementary regulatory recommendations, this step is essential for ensuring that all relevant leachables are identified and characterized.

Step 2: Selection of Analytes and Surrogates

With a clear scope defined, the next step is the selection of analytes and surrogates for extractables and leachables testing. Analytes are the specific leachables that will be tested, while surrogates are compounds used to represent the leachables that may be present, aiding in the testing process.

When selecting analytes:

  • Consider the chemical structure and properties of materials in contact with the drug formulation.
  • Identify prior analytical data from similar products or studies.
  • Consult relevant literature and industry standards.
  • Account for regulatory expectations related to known toxicants.

Surrogates should be chosen judiciously, as they can assist in predicting the presence and behavior of otherwise difficult-to-analyze leachables. The establishment of a robust surrogate analysis method can help in informing decisions regarding production and regulatory compliance.

Step 3: Conduct an AET/DBT Calculation

Evaluating the outcomes from the analytes and surrogates selected, it becomes essential to compute the AET and DBT. To perform this calculation, follow these guidelines:

  • Determine the Toxicology Data: Compile toxicological information about each analyte.
  • Conduct Dose Calculations: Based on the drug product dosage and route of administration, determine exposure levels.
  • Establish Margin of Safety: Use toxicological data and exposure calculations to confirm that any identified leachables are below the AET and DBT thresholds.

These calculations serve as a foundation for establishing a scientifically justified safety profile for leachables present in pharmaceutical products. This step assures stakeholders of compliance with FDA process validation and EU GMP expectations and enhances confidence in product quality and safety.

Step 4: Method Development and Validation of Analytical Techniques

Once the analytes and surrogates are selected, method development must occur to ensure reliable E&L testing. Analytical techniques commonly employed include:

  • Gas Chromatography-Mass Spectrometry (GC-MS): Ideal for volatile and semi-volatile compounds.
  • High-Performance Liquid Chromatography (HPLC): Suitable for non-volatile compounds.
  • Liquid Chromatography-Mass Spectrometry (LC-MS): Widely used for polar and thermally labile compounds.

It is imperative to validate these analytical methods to confirm their accuracy, specificity, precision, and robustness. Validation should follow guidelines provided by the USP and be consistent with any applicable regulatory guidelines, including those of the EMA and MHRA. This validation process assures that methods are fit for purpose and results are both reliable and robust.

Step 5: Data Analysis and Reporting

The analysis phase involves performing the quantitative assessments of the identified leachables to determine their concentrations within the drug product. Data generated from these analyses must be critically evaluated to ascertain compliance with established safety thresholds, including the AET and DBT. Reporting this data should include the following:

  • Identified Leachables: Clearly describe the leachables detected and their respective concentrations.
  • Comparison with AET/DBT: Discuss the implications of findings concerning the thresholds.
  • For Contingent Findings: Provide interpretations of any concentrations that approach or exceed allowable limits.

A well-structured report not only aligns with regulatory expectations but also facilitates informed decision-making for risk management and compliance actions.

Conclusion: Ensuring Compliance with E&L Testing Frameworks

The execution of targeted leachables studies is a critical component in ensuring the integrity and safety of pharmaceutical products. Following a systematic approach to the selection of analytes and surrogates, along with solid AET/DBT calculations, method development and validation, and thorough reporting, provides a pathway toward meeting regulatory compliance and safeguarding patient health.

As E&L testing practices evolve, maintaining awareness of updates to regulatory expectations and best practices will be imperative for pharma professionals, clinical operations, and regulatory affairs specialists. Emphasizing a robust validation framework not only strengthens the quality framework of drug products but also enhances confidence in their safety and efficacy.